#United States #New York #Lucid Diagnostics #EsoGuard #PAVmed

Lucid Diagnostics Completes $15.3 Million Direct Stock Offering

Lucid Diagnostics Inc. (Nasdaq: LUCD), a notable player in the cancer prevention medical diagnostics landscape, has completed a registered direct offering that raised approximately $15.3 million. This initiative serves as a significant step in bolstering the company's working capital and supporting its corporate goals.

Details of the Offering

On March 5, 2025, Lucid Diagnostics announced that it had closed its previously declared direct offering. The company issued 13,939,331 shares of common stock at an attractive purchase price of $1.10 per share. Following the deduction of placement agent fees, which totaled around $0.8 million, the net proceeds from this offering will primarily go toward enhancing Lucid's operational capabilities and fulfilling other corporate obligations. Canaccord Genuity acted as the sole placement agent for this strategic financial maneuver.

This offering was made under an effective registration statement on Form S-3, which the Securities and Exchange Commission (SEC) initially declared effective back in December 2022. Additional information regarding the offering can be accessed through the SEC's official website, ensuring transparency for investors and stakeholders alike.

About Lucid Diagnostics

Lucid Diagnostics is dedicated to combating esophageal cancer, focusing on patients suffering from gastroesophageal reflux disease (GERD), commonly characterized by chronic heartburn. This condition significantly raises the risk of developing precancerous changes in the esophagus. Lucid's transformative diagnostic tools, particularly the EsoGuard® Esophageal DNA Test, are groundbreaking in their approach, as they empower healthcare professionals to detect signs of precancer early in at-risk patients.

Using the EsoCheck® Esophageal Cell Collection Device, the EsoGuard® test allows for a minimally invasive sample collection procedure that can be conducted comfortably in a healthcare setting. This is a major advancement in early cancer detection, aiming to prevent cancer development and associated fatalities.

Future Endeavors

The capital raised from this stock offering will play a vital role in expanding Lucid’s operational scope. As the company seeks to improve patient care and diagnosis accuracy, these funds will directly support their mission to facilitate early detection of esophageal cancer. By investing in working capital and expanding their reach, Lucid Diagnostics aims to set a higher standard in cancer prevention and healthcare outcomes.

To learn more about Lucid Diagnostics and their innovative approaches to cancer detection, please visit their official website at luciddx.com. For insights into their parent company, PAVmed Inc., additional information can also be found at pavmed.com. Through strategic financial movements and commitment to medical advancements, Lucid Diagnostics is poised to make significant contributions to patient health and cancer prevention strategies.

Overall, the completion of the $15.3 million stock offering represents not just a financial boost for Lucid Diagnostics but also a commitment to their overarching goal of advancing public health through innovative medical diagnostics and early intervention strategies.